Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 35

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective

Han, Xin, Wei, Wenyi, Sun, Yi·2022·Acta Materia Medica

Abstract

Mouse double minute 2 (MDM2) is an oncogenic E3 ligase that effectively degrades the tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt MDM2-p53 binding have been discovered and developed. Given that MDM2 and p53 form an auto-regulatory loop, in which p53 undergoes targeted degradation as a substrate of MDM2, and p53 targets MDM2 for transcriptional upregulation, these MDM2 inhibitors have limited efficacy. After rapid in vivo clearance of the MDM2 inhibitors, p53 is degraded by accumulated MDM2. Fortunately, proteolysis targeting chimeras (PROTACs), a novel therapeutic strategy, overcome the limitations of MDM2 inhibitors. Several MDM2 inhibitors developed in the past two decades have been used in PROTAC technology in two applications: 1) binding and targeting endogenous MDM2 for PROTAC-based degradation and 2) binding endogenous MDM2 as a PROTAC E3 ligand for PROTAC-based degradation of other oncogenic proteins. In this review, we summarize current progress in the discovery and development of MDM2-based PROTAC drugs, and discuss future perspectives and challenges in their application as effective treatments for human cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15212/amm-2022-0010

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 82

  1. RM Mohammad, 2009, An MDM2 Antagonist (MI-319) Restores p53 Functions and Increases the Life Span of Orally Treated Follicular Lymphoma Bearing Animals, Molecular Cancer, 8, 115, 10.1186/1476-4598-8-115 · DOI
  2. LT Vassilev, 2004, In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
  3. S Shangary, 2008, Targeting the MDM2-p53 Interaction for Cancer Therapy, Clinical Cancer Research, 14, 5318, 10.1158/1078-0432.CCR-07-5136 · DOI · Paper page
  4. S Kumari, 2022, Therapeutic Potential of p53 Reactivation in Prostate Cancer: Strategies and Opportunities, European Journal of Pharmacology, 919, 10.1016/j.ejphar.2022.174807 · DOI
  5. S Nag, 2014, Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?, Current Medicinal Chemistry, 21, 553, 10.2174/09298673113206660325 · DOI
  6. AB Herrero, 2016, Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma, International Journal of Molecular, 17, 2003
  7. Chao, 2015, Mechanisms of p53 Degradation, Clinica Chimica Acta, 438, 139, 10.1016/j.cca.2014.08.015 · DOI
  8. J Hu, 2021, Targeting Mutant p53 for Cancer Therapy: Direct and Indirect Strategies, Journal of Hematology and Oncology, 14, 157, 10.1186/s13045-021-01169-0 · DOI · Paper page
  9. R Rusiecki, 2019, MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010–Present), Recent Patents on Anti-Cancer Drug Discovery, 14, 324, 10.2174/1574892814666191022163540 · DOI
  10. A Burgess, 2016, Clinical Overview of MDM2/X-Targeted Therapies, Frontiers in Oncology, 6, 7, 10.3389/fonc.2016.00007 · DOI · Paper page
  11. S Zhang, 2021, Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions, Journal of Medicinal Chemistry, 64, 10621, 10.1021/acs.jmedchem.1c00940 · DOI
  12. J Myung, 2001, The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors, Medicinal Research Reviews, 21, 245, 10.1002/med.1009 · DOI · Paper page
  13. Z Yang, 2021, Merging PROTAC and Molecular Glue for Degrading BTK and GSPT1 Proteins Concurrently, Cell Research, 31, 1315, 10.1038/s41422-021-00533-6 · DOI
  14. K Garber, 2022, The PROTAC Gold Rush, Nature Biotechnology, 40, 12, 10.1038/s41587-021-01173-2 · DOI
  15. S He, 2022, Strategies for Designing Proteolysis Targeting Chimaeras (PROTACs), Medicinal Research Reviews, 42, 1280, 10.1002/med.21877 · DOI
  16. M Bekes, 2022, PROTAC Targeted Protein Degraders: The Past is Prologue, Nature Reviews Drug Discovery, 21, 181, 10.1038/s41573-021-00371-6 · DOI · Paper page
  17. T Neklesa, 2019, ARV-110: An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer, Journal of Clinical Oncology, 37, 259, 10.1200/JCO.2019.37.7_suppl.259 · DOI · Paper page
  18. W Xiang, 2021, Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer, Journal of Medicinal Chemistry, 64, 13487, 10.1021/acs.jmedchem.1c00900 · DOI
  19. X Yu, 2021, Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders, Journal of Medicinal Chemistry, 64, 18054, 10.1021/acs.jmedchem.1c01476 · DOI
  20. X Han, 2019, Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands, Journal of Medicinal Chemistry, 62, 11218, 10.1021/acs.jmedchem.9b01393 · DOI · Paper page
  21. LJ Zhao, 2020, A Highly Potent PROTAC Androgen Receptor (AR) Degrader ARD-61 Effectively Inhibits AR-Positive Breast Cancer Cell Growth in Vitro Tumor Growth in Vivo, Neoplasia, 22, 522, 10.1016/j.neo.2020.07.002 · DOI
  22. S Kregel, 2020, Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment, Neoplasia, 22, 111, 10.1016/j.neo.2019.12.003 · DOI
  23. X Han, 2019, Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer, Journal of Medicinal Chemistry, 62, 941, 10.1021/acs.jmedchem.8b01631 · DOI · Paper page
  24. J Hu, 2019, Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER), Journal of Medicinal Chemistry, 62, 1420, 10.1021/acs.jmedchem.8b01572 · DOI · Paper page
  25. L Bai, 2019, A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo, Cancer Cell, 36, 498, 10.1016/j.ccell.2019.10.002 · DOI · Paper page
  26. Y Zou, 2019, The PROTAC Technology in Drug Development, Cell Biochemistry & Function, 37, 21, 10.1002/cbf.3369 · DOI · Paper page
  27. CY Yang, 2019, Small-Molecule PROTAC Degraders of the Bromodomain and Extra Terminal (BET) Proteins – A Review, Drug Discovery Today Technologies, 31, 43, 10.1016/j.ddtec.2019.04.001 · DOI
  28. JS Schneekloth, 2004, Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation, Journal of the American Chemical Society, 126, 3748, 10.1021/ja039025z · DOI · Paper page
  29. D Bernard, 2012, AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development, Journal of Medicinal Chemistry, 55, 4934, 10.1021/jm3007068 · DOI
  30. Y Zhao, 2013, A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice, Journal of Medicinal Chemistry, 56, 5553, 10.1021/jm4005708 · DOI · Paper page
  31. A Zafar, 2021, Targeting the p53-MDM2 Pathway for Neuroblastoma Therapy: Rays of Hope, Cancer Letters, 496, 16, 10.1016/j.canlet.2020.09.023 · DOI
  32. W Wang, 2012, Small Molecule Agents Targeting the p53-MDM2 Pathway for Cancer Therapy, Medicinal Research Reviews, 32, 1159, 10.1002/med.20236 · DOI
  33. GM Popowicz, 2011, The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious, Angewandte Chemie International Edition in English, 50, 2680, 10.1002/anie.201003863 · DOI · Paper page
  34. C Tovar, 2013, MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models, Cancer Research, 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
  35. B Vu, 2013, Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development, ACS Medicinal Chemistry Letters, 4, 466, 10.1021/ml4000657 · DOI · Paper page
  36. M de Jonge, 2017, A Phase I Study of SAR405838, A Novel Human Double Minute 2 (HDM2) Antagonist, in Patients with Solid Tumours, European Journal of Cancer, 76, 144, 10.1016/j.ejca.2017.02.005 · DOI · Paper page
  37. J Jung, 2016, TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated Liposarcoma, Nature Communication, 7, 10.1038/ncomms12609 · DOI · Paper page
  38. M Konopleva, 2020, MDM2 Inhibition: An Important Step Forward in Cancer Therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
  39. Y Liu, 2019, The Past, Present and Future of Potential Small-Molecule Drugs Targeting p53-MDM2/MDMX for Cancer Therapy, European Journal of Medicinal Chemistry, 176, 92, 10.1016/j.ejmech.2019.05.018 · DOI
  40. T Stachyra-Valat, 2016, NVP-HDM201: Biochemical and Biophysical Profile of a Novel Highly Potent and Selective PPI Inhibitor of p53-Mdm2, Cancer Research, 76, 1239, 10.1158/1538-7445.AM2016-1239 · DOI · Paper page
  41. MM Gounder, 2016, A Phase 1 Study of the MDM2 Inhibitor DS-3032b in Patients (pts) with Advanced Solid Tumors and Lymphomas, Journal of Clinical Oncology, 34, 2581, 10.1200/JCO.2016.34.15_suppl.2581 · DOI
  42. CD DiNardo, 2016, Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies – Preliminary Results, Blood, 128, 593, 10.1182/blood.V128.22.593.593 · DOI
  43. L Zhang, 2019, A Novel Small Molecule Inhibitor of MDM2-p53 (APG-115) has Antitumor Activity in Gastric Adenocarcinoma, Cancer Research, 79, 2061, 10.1158/1538-7445.AM2019-2061 · DOI
  44. H Yi, 2018, A Novel Small Molecule Inhibitor of MDM2-p53 (APG-115) Enhances Radiosensitivity of Gastric Adenocarcinoma, Journal of Experimental & Clinical Cancer Research, 37, 97, 10.1186/s13046-018-0765-8 · DOI · Paper page
  45. F Ravandi, 2016, A Phase I Trial of the Human Double Minute 2 Inhibitor (MK-8242) in Patients with Refractory/Recurrent Acute Myelogenous Leukemia (AML), Leukemia Research, 48, 92, 10.1016/j.leukres.2016.07.004 · DOI · Paper page
  46. T Valat, 2014, Mechanistic Study of NVP-CGM097: A Potent, Selective and Species Specific Inhibitor of p53-Mdm2, Cancer Research, 74, 1798, 10.1158/1538-7445.AM2014-1798 · DOI
  47. F Gessier, 2015, Discovery of Dihydroisoquinolinone Derivatives as Novel Inhibitors of the p53-MDM2 Interaction with a Distinct Binding Mode, Bioorganic and Medicinal Chemistry Letters, 25, 3621, 10.1016/j.bmcl.2015.06.058 · DOI
  48. Y Wang, 2014, Optimization Beyond AMG 232: Discovery and SAR of Sulfonamides on a Piperidinone Scaffold as Potent Inhibitors of the MDM2-p53 Protein-Protein Interaction, Bioorganic and Medicinal Chemistry Letters, 24, 3782, 10.1016/j.bmcl.2014.06.073 · DOI
  49. SM Picksley, 1993, The p53-mdm2 Autoregulatory Feedback Loop: A Paradigm for the Regulation of Growth Control by p53?, Bioessays, 15, 689, 10.1002/bies.950151008 · DOI · Paper page
  50. GM Burslem, 2017, Small-Molecule Modulation of Protein Homeostasis, Chemical Reviews, 117, 11269, 10.1021/acs.chemrev.7b00077 · DOI · Paper page
  51. M Toure, 2016, Small-Molecule PROTACS: New Approaches to Protein Degradation, Angewandte Chemie International Edition, 55, 1966, 10.1002/anie.201507978 · DOI · Paper page
  52. AC Lai, 2016, Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL, Angewandte Chemie International Edition, 55, 807, 10.1002/anie.201507634 · DOI · Paper page
  53. PM Cromm, 2017, Targeted Protein Degradation: From Chemical Biology to Drug Discovery, Cell Chemical Biology, 24, 1181, 10.1016/j.chembiol.2017.05.024 · DOI · Paper page
  54. AC Lai, 2017, Induced Protein Degradation: An Emerging Drug Discovery Paradigm, Nature Reviews Drug Discovery, 16, 101, 10.1038/nrd.2016.211 · DOI · Paper page
  55. H Inuzuka, 2022, PROTAC Technology for the Treatment of Alzheimer’s Disease: Advances and Perspectives, Acta Materia Medica, 1, 24, 10.15212/AMM-2021-0001 · DOI
  56. J Liu, 2021, Cancer Selective Target Degradation by Folate-Caged PROTACs, Journal of the American Chemical Society, 143, 7380, 10.1021/jacs.1c00451 · DOI · Paper page
  57. A Testa, 2018, 3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation, Journal of the American Chemical Society, 140, 9299, 10.1021/jacs.8b05807 · DOI
  58. M Slabicki, 2020, Small-Molecule-Induced Polymerization Triggers Degradation of BCL6, Nature, 588, 164, 10.1038/s41586-020-2925-1 · DOI · Paper page
  59. F Yu, 2021, Targeting Protein Kinases Degradation by PROTACs, Frontiers in Chemistry, 9
  60. H Li, 2022, Drug Discovery is an Eternal Challenge for the Biomedical Sciences, Acta Materia Medica, 1, 1
  61. MJ Bond, 2021, Proteolysis Targeting Chimeras (PROTACs) Come of Age: Entering the Third Decade of Targeted Protein Degradation, RSC Chemical Biology, 2, 725, 10.1039/D1CB00011J · DOI · Paper page
  62. JC Groppe, 2019, Induced Degradation of Protein Kinases by Bifunctional Small Molecules: a Next-Generation Strategy, Expert Opinion on Drug Discovery, 14, 1237, 10.1080/17460441.2019.1660641 · DOI
  63. X Sun, 2019, PROTACs: Great Opportunities for Academia and Industry, Signal Transduction and Targeted Therapy, 4, 64, 10.1038/s41392-019-0101-6 · DOI · Paper page
  64. B Wang, 2021, Development of MDM2 Degraders Based on Ligands Derived From Ugi Reactions: Lessons and Discoveries, European Journal of Medicinal Chemistry, 219, 10.1016/j.ejmech.2021.113425 · DOI · Paper page
  65. B Zhang, 2015, Small-Molecule MDM2-p53 Inhibitors: Recent Advances, Future Medicinal Chemistry, 7, 631, 10.4155/fmc.15.13 · DOI
  66. Q Zhao, 2019, Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells by a PARP1-Targeting PROTAC Small Molecule, Chemical Communications (Camb), 55, 369, 10.1039/C8CC07813K · DOI · Paper page
  67. L Bai, 2017, Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer, Cancer Research, 77, 2476, 10.1158/0008-5472.CAN-16-2622 · DOI · Paper page
  68. N Ohoka, 2019, Development of Small Molecule Chimeras that Recruit Arylhydrocarbon Receptor (AhR) E3 Ligase to Induce Degradation of Target Proteins, Molecular Cancer Therapeutics, 18, C125, 10.1158/1535-7163.TARG-19-C125 · doi:10.1158/1535-7163.targ-19-c125
  69. M Zengerle, 2015, Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4, ACS Chemical Biology, 10, 1770, 10.1021/acschembio.5b00216 · DOI · Paper page
  70. KH Chan, 2018, Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds, Journal of Medicinal Chemistry, 61, 504, 10.1021/acs.jmedchem.6b01912 · DOI · Paper page
  71. F Li, 2022, Poly (ADP-ribose) Polymerase 1 (PARP1) Inhibition Promotes Pulmonary Metastasis of Osteosarcoma by Boosting Ezrin Phosphorylation, International Journal of Biological Sciences, 18, 1238, 10.7150/ijbs.58784 · DOI
  72. S Challa, 2022, Two Birds, One Stone: Non-canonical Therapeutic Effects of the PARP Inhibitor Talazoparib, Cell Chemical Biology, 29, 171, 10.1016/j.chembiol.2022.02.002 · doi:10.1016/j.chembiol.2022.02.002
  73. M Mekhaeil, 2022, Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases, Cancers (Basel), 14, 687, 10.3390/cancers14030687 · DOI
  74. Y Jia, 2021, Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells, Frontiers in Oncology, 11
  75. X Zhang, 2020, Design and Synthesis of Selective Degraders of EGFR(L858R/T790M) Mutant, European Journal of Medicinal Chemistry, 192, 10.1016/j.ejmech.2020.112199 · DOI
  76. B Zhao, 2019, TrkC-Targeted Kinase Inhibitors and PROTACs, Molecular Pharmaceutics, 16, 4313, 10.1021/acs.molpharmaceut.9b00673 · DOI
  77. M Zheng, 2021, Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP, Journal of Medicinal Chemistry, 64, 7839, 10.1021/acs.jmedchem.1c00649 · DOI · Paper page
  78. WH Guo, 2020, Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry, Nature Communications, 11, 4268, 10.1038/s41467-020-17997-6 · DOI · Paper page
  79. D Takahashi, 2019, AUTACs: Cargo-Specific Degraders Using Selective Autophagy, Molecular Cell, 76, 797, 10.1016/j.molcel.2019.09.009 · DOI · Paper page
  80. B Ma, 2022, Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia, Advanced Science (Weinh), 9
  81. G Nishiguchi, 2021, Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators, Journal of Medicinal Chemistry, 64, 7296, 10.1021/acs.jmedchem.0c01313 · DOI
  82. B Halford, 2021, Arvinas Unveils PROTAC Structures, Chemical and Engineering News, 99, 5, 10.47287/cen-09914-scicon1 · DOI

Cited by

See all 35

Metadata

Authors
Han, X., Wei, W., & Sun, Y.
Venue
Acta Materia Medica
Published
2022
Volume
1
Issue
2
ISSN
2737-7946
Cited by
35
References
37
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. https://app.cochat.ai/papers/10.15212/amm-2022-0010
The paper
Han, X., Wei, W., & Sun, Y. (2022). PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective. Acta Materia Medica. https://doi.org/10.15212/amm-2022-0010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.